Pfizer And EpiPen Consumers Reach $345M Deal

By J. Edward Moreno (July 15, 2021, 6:29 PM EDT) -- Pfizer has reached a $345 million settlement with a class of consumers who allege they overpaid for EpiPens because of anti-competitive practices by pharmaceutical companies, potentially clearing the company from having to face a jury trial scheduled for early next year....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!